Navigation Links
Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
Date:9/26/2011

DENVER and PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that the company's lead investigational product for postsurgical pain management, EXPAREL™ (bupivacaine liposome extended-release injectable suspension), was highlighted in the "Hot Topics in Plastic Surgery" panel at the annual scientific assembly of the American Society of Plastic Surgeons (ASPS) in Denver, Colo. In addition, new data demonstrating the long-term safety of EXPAREL following augmentation mammoplasty (breast augmentation) using silicone implants were presented during an oral session at ASPS.

Currently under review with the U.S. Food and Drug Administration, EXPAREL is an innovative long-acting bupivacaine that has been shown in multiple Phase 2 and Phase 3 clinical studies to provide prolonged postsurgical analgesia for up to 72 hours with a single-dose local administration at the surgical site. The drug combines bupivacaine with DepoFoam®, a proven product delivery technology that encapsulates medications and delivers them over a desired time period.

Richard A. Baxter, M.D., a practicing plastic surgeon in the Seattle area and former president of the Washington Society of Plastic Surgeons and the Northwest Society of Plastic Surgeons, presented an overview of EXPAREL, including the clinical efficacy data to date, at the "Hot Topics in Plastic Surgery" panel on Friday, September 23, 2011.

"Patient safety, comfort and satisfaction are of primary importance to surgeons and to the success of their practices," said Dr. Baxter. "The thought of postsurgical pain is one of the biggest impediments for patients considering elective operations such as cosmetic plastic surgery. Traditional opioid medications have a long list of drawbacks including nausea, constipation and inconsistent pain
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Calif., Feb. 27, 2015 Isis Pharmaceuticals, Inc. ... outperformed both its pro forma net operating loss (NOL) ... a strong financial position.  Isis, significantly improved financial results ... $230 million in payments the Company received from its ... 2014 was a nearly 60% improvement over its 2013 ...
(Date:2/27/2015)... N.J. , Feb. 27, 2015 An ... has helped cut the rate of infection with a ... 40 percent. Clostridium difficile, or C.diff, is ... to life-threatening inflammation of the colon. A recent article ... of Clostridium difficile Infection in the United ...
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... , ABBOTT PARK, Ill., Feb. 11 Abbott ... and Drug Administration (FDA) has granted approval of a new tablet ... Norvir tablets can be stored at room temperature and ... Norvir tablets and the Norvir soft-gelatin capsules both contain 100 mg ...
... , , HONG KONG , Feb. ... been enrolled in a randomized clinical trial of the Genous Bio-engineered ... study, the trial will enroll 180 patients split evenly between the ... primary study objective is to demonstrate the safety and effectiveness of ...
Cached Medicine Technology:Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 2Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 3Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 4Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 5Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 6Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 7Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 8Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 9Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 10Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 11Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 12Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 13OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China 2OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China 3
(Date:2/27/2015)... 27, 2015 On March 2-4, ... the National Cancer Institute (NCI) will co-host the ... National Institutes of Health (NIH), in Bethesda, Maryland. ... dedicated to medical professionals and scientists who specialize ... the general public, including patients, their families, and ...
(Date:2/27/2015)... 27, 2015 In honor of American Heart Month ... (CPC) South office, is offering tips on how to improve heart ... but that doesn't mean people have to accept it as their ... factors — such as family history, sex or age — there ... Dr. Scott has six helpful tips to improve heart health and ...
(Date:2/27/2015)... Freeport, ME (PRWEB) February 27, 2015 Royal ... Freeport, ME, reports a new study that found adults who ... to develop type 2 diabetes compared to those who got ... elevated blood sugar levels. , The report is part of ... Being® ,” which Royal River Natural Foods publishes free each ...
(Date:2/27/2015)... 27, 2015 Adding to its ... pharmaceuticals, Benedict Advertising & Marketing has added Sedation ... The company’s patented NITROUSEAL® N20 closed mask and ... of sedation. , Sedation Systems, http://www.sedationsystems.com ... a new level, though it focuses primarily on ...
(Date:2/27/2015)... 27, 2015 FACE Skincare~Medical~Wellness, a ... announced a unique combination to take fifteen years ... Décolletage is a new treatment introduced that is ... specifically indicated to improve lines and wrinkles on ... person who suffers from the stubborn vertical lines ...
Breaking Medicine News(10 mins):Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Center for Primary Care Celebrates American Heart Month 2Health News:Center for Primary Care Celebrates American Heart Month 3Health News:Center for Primary Care Celebrates American Heart Month 4Health News:New Study Finds Magnesium May Slow Progress of Diabetes, Retailer Reports 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:Face Skincare Announces New Combination Therapy 2
... older brothers and sisters can be tough work, as any youngest ... at the University of North Carolina at Chapel Hill shows that ... sympathies for the first born or rather, first laid ... issue of PLoS ONE, runs somewhat counter to common wisdom, which ...
... demands solutions from presidential candidates, Congress, ... Independent Business (NFIB), the nation,s leading small ... Start Here, an,aggressive healthcare campaign that will ... reform for small business. Kicking off the,campaign, ...
... its Weight Watchers program and obesity training, state,s,largest Medicaid ... Association to provide medical professionals the opportunity ... certified in conducting Breathe Well, Live Well program, ... rank among the highest in the country in asthma ...
... Eating a Bowl May Increase Attentiveness by Nearly 20 Percent, ... going,to great lengths to help their kids do their best ... learning software and pack their,schedules with enrichment activities. While all ... one of the simplest ways to help,ensure their kids do ...
... 12 BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced ... present a,company update at the Lehman Brothers Global Healthcare ... p.m. ET., Interested parties may access a live ... the BioMarin website, http://www.BMRN.com . A,replay of the ...
... VIEW, Calif., March 12 Omnicell,Inc. (Nasdaq: OMCL ... facilities, announced today that it has completed its $40.0,million ... total of,2,133,898 shares were repurchased at an average price ... OMCL ) is a leading provider of systems ...
Cached Medicine News:Health News:Early bird doesn't always get worm, UNC researcher finds 2Health News:National Federation of Independent Business Launches Aggressive Campaign to Drive Healthcare Reform: Solutions Start Here 2Health News:National Federation of Independent Business Launches Aggressive Campaign to Drive Healthcare Reform: Solutions Start Here 3Health News:National Federation of Independent Business Launches Aggressive Campaign to Drive Healthcare Reform: Solutions Start Here 4Health News:UniCare of West Virginia Providing Assistance for Asthma Education Training 2Health News:UniCare of West Virginia Providing Assistance for Asthma Education Training 3Health News:Help Your Kids Earn an 'A' for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast 2Health News:Help Your Kids Earn an 'A' for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast 3Health News:Help Your Kids Earn an 'A' for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast 4Health News:BioMarin to Present at the Lehman Brothers Global Healthcare Conference 2Health News:Omnicell Announces Completion of Its Common Stock Repurchase Plan 2
... The CMGS-1 Color Mini-Ganzfeld Stimulator is ... can be integrated with your existing LKC ... with other visual electrodiagnostic test systems. ... is the smallest commercial Ganzfeld to meet ...
... the most advanced visual electrodiagnostic system ... of retinal and optic nerve function. ... drives this powerful computer-controlled instrument. With ... pattern stimulation, rapid Ganzfeld flash rate ...
... designed to facilitate an arthrodesis, either by ... interbody cages allowing radicular compression by restoring ... and of the foramina, which in turn ... for major lumbar instabilities.,CC cages are made ...
... SHELLGEL is a sterile nonpyrogenic, transparent ... SHELLGEL contains 12 mg/mL of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: